Πλοήγηση ανά Θέμα "WORKING GROUP"

Αποτελέσματα 1-1 από 1

Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group

Katodritou, E.; Terpos, E.; Kelaidi, C.; Kotsopoulou, M.; Delimpasi, S.; Kyrtsonis, M. C.; Symeonidis, A.; Giannakoulas, N.; Stefanoudaki, A.; Christoulas, D.; Chatziaggelidou, C.; Gastari, V.; Spyridis, N.; Verrou, E.; Konstantinidou, P.; Zervas, K.; Dimopoulos, M. A. (2014)

Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety ...